|
[Related PubMed/MEDLINE]
Total Number of Papers: 162
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
|
--- |
| 2 |
2022 |
A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke. |
ADP-PAg, AIS, LOF, PCR, PRI, VASP |
| 3 |
2022 |
Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial. |
MEA, STEMI, VASP-P |
| 4 |
2022 |
Circulating Microvesicles in Convalescent Ischemic Stroke Patients: A Contributor to High-On-Treatment Residual Platelet Reactivity? |
AUC, PMVs |
| 5 |
2022 |
Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response. |
BMI, LD |
| 6 |
2022 |
Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study). |
LTA, PAgR, TEG |
| 7 |
2022 |
High on-treatment platelet reactivity is associated with poor outcomes after ischemic stroke: A meta-analysis. |
NIHSS, RR, TIA |
| 8 |
2022 |
High on-treatment platelet reactivity to aspirin in patients after myocardial infarction. |
--- |
| 9 |
2022 |
High On-Treatment Platelet Reactivity: Aspirin versus Clopidogrel. |
MoA, OAC, PCI, SAPT |
| 10 |
2022 |
High triglyceride is an independent predictor of high on-treatment platelet reactivity in ischemic stroke patients. |
ADPi, CI, DAPT, IS, NTPR, OR, TEG, TG |
| 11 |
2022 |
Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis. |
ACS, LD, LTPR, MEA, MTD, PR, VASP |
| 12 |
2022 |
Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention. |
ACS, CAD, LTPR, NTPR, PCI, TP, TPR |
| 13 |
2021 |
A Systematic Review and Meta-Analysis on the Impact of High On-Treatment Platelet Reactivity on Clinical Outcomes for Patients Taking ADP Receptor Inhibitors Following Lower Limb Arterial Endovascular Intervention. |
ADP, GRADE |
| 14 |
2021 |
Aspirin I.V. Loading during Elective Percutaneous Coronary Intervention. |
ASA, CI, MACCE, MACCEs, MoA, OR, PCIs |
| 15 |
2021 |
Association between renal function and platelet reactivity during aspirin therapy in elderly patients with atherosclerotic cardiovascular disease. |
eGFR |
| 16 |
2021 |
High On-Treatment Platelet Reactivity as Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents. |
--- |
| 17 |
2021 |
Impact of high on-treatment platelet reactivity after angioplasty in patients with critical limb ischemia. |
CLI, DAPT, LTA, MACCE, MALE, PAD, PTA, VASP |
| 18 |
2021 |
Novel Predictors of Future Vascular Events in Post-stroke Patients-A Pilot Study. |
LB, mPFT, NAR, WB |
| 19 |
2021 |
Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China. |
ADP, CHD, hs-CRP, LTPR, PCI, TEG |
| 20 |
2021 |
[Effect of platelet reactivity on clinical events in patients using bivalirudin in selective percutaneous coronary intervention]. |
BARC, LTPR, MAADP, MACCE, NTPR, PCI, TEG |
| 21 |
2020 |
Aspirin Resistance Affects Medium-Term Recurrent Vascular Events after Cerebrovascular Incidents: A Three-Year Follow-up Study. |
CI, HR, NTPR, OR |
| 22 |
2020 |
Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: An observational study. |
ADP, LOF, LTA |
| 23 |
2020 |
Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease. |
CAD, EMs, FMO3, IMs, LD, MD, PCR-RFLP, PMs, PRI |
| 24 |
2020 |
Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke. |
ADP, IS, PRU, SNPs, TIAs |
| 25 |
2020 |
Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis. |
ACS, CI, MACEs, MI, PCI, RCTs, RR, ST, TVR |
| 26 |
2020 |
Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption. |
--- |
| 27 |
2020 |
Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. |
CI, DAPT, HR, LTA, MACCE, MALE, PAD, VASP |
| 28 |
2020 |
Intake of aspirin prior to metamizole does not completely prevent high on treatment platelet reactivity. |
AA, COX-1, IA, LTA |
| 29 |
2020 |
Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients. |
MA, MAadp, PCI, TEGaradp, TEGpm |
| 30 |
2020 |
Outcomes and strategy of tailored antiplatelet therapy with ticagrelor in patients undergoing transcarotid artery revascularization. |
DAPT, TCAR |
| 31 |
2020 |
Should CYP2C19 Genotyping Be Recommended as a Straight Forward Approach to Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by Type 2 Diabetes Mellitus? |
CI, IS, OR, PCR-RFLP, PIADP, T2DM, TEG |
| 32 |
2019 |
Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation. |
DAPT |
| 33 |
2019 |
Between a rock and a hard place: a high-risk patient with resistance to multiple P2Y12 antagonists. |
LOF, LVAD |
| 34 |
2019 |
Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events. |
MACEs |
| 35 |
2019 |
Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. |
CAD, MACCE, MoA, NSTEMI |
| 36 |
2019 |
Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI. |
ACS, HR, MI, PCI, ST, STD, TVR |
| 37 |
2019 |
Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study). |
ACS, ADP, IR, LTA, TEG |
| 38 |
2019 |
Platelet reactivity patterns in patients treated with dual antiplatelet therapy. |
AA, ACS, ADP, DAPT |
| 39 |
2019 |
Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. |
LTPR |
| 40 |
2019 |
[Relation of Functional Activity of Platelets to Prognosis of Unfavorable Cardiovascular Events in Patients with Acute Coronary Syndrome. Results of a Registry Study]. |
ACS |
| 41 |
2018 |
CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. |
CAD, DAPT, LD, MD, NTPR, PCI, PCR-RFLP, PRI, SNPs |
| 42 |
2018 |
Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyrone co-medicated chronic artery disease patients. |
AA, CAD, LTA |
| 43 |
2018 |
Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. |
PAD |
| 44 |
2018 |
Effectiveness of Platelet Function Analyzer-100 for Laboratory Detection of Anti-Platelet Drug-Induced Platelet Dysfunction. |
CT, NSAIDs, PFA |
| 45 |
2018 |
H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review. |
DAPT, GI, H2RAs, MACE, PPIs |
| 46 |
2018 |
High On-Treatment Platelet Reactivity in Danish Hyper-Acute Ischaemic Stroke Patients. |
IS, TIAs |
| 47 |
2018 |
Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment. |
DAPT, IPF, PCIs |
| 48 |
2018 |
Malondialdehyde Assay in the Evaluation of Aspirin Antiplatelet Effects. |
LTA, MDA, TX |
| 49 |
2018 |
Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. |
OR |
| 50 |
2018 |
Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients. |
CAD, DAPT, IAP, LD, PCI |
| 51 |
2018 |
Platelet function testing: dead or alive. |
LTA, LTPR, MP, VASP |
| 52 |
2018 |
Risk of discontinuation of clopidogrel after 1 month following bare-metal stents: a propensity-score adjusted comparison with continued administration of clopidogrel after drug-eluting stents. |
BMS, MI, PCI |
| 53 |
2018 |
Role of Dipyrone in the High On-Treatment Platelet Reactivity amongst Acetylsalicylic Acid-Treated Patients Undergoing Peripheral Artery Revascularisation. |
ASA |
| 54 |
2018 |
Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. |
AMI, IS, TIA |
| 55 |
2017 |
1H NMR based pharmacometabolomics analysis of urine identifies metabolic phenotype of clopidogrel high on treatment platelets reactivity in coronary artery disease patients. |
CAD, LD |
| 56 |
2017 |
Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial. |
ASA, TXB2 |
| 57 |
2017 |
Add-on Antiplatelet Effects of Eicosapentaenoic Acid With Tailored Dose Setting in Patients on Dual Antiplatelet Therapy. |
AA, EPA, MPA |
| 58 |
2017 |
Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI. |
PCI, PRU |
| 59 |
2017 |
Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. |
ADP, CCBs, CI, DM, OR, PPIs |
| 60 |
2017 |
Evaluation of On-Clopidogrel platelet reactivity overtime, SYNTAX SCORE, genetic polymorphisms and their relationship to one year clinical outcomes in STEMI patients undergoing PCI. |
MACE, PAI, PCI, SS, STEMI |
| 61 |
2017 |
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. |
ACS, LOF |
| 62 |
2017 |
Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. |
ACS, ADP, TEG |
| 63 |
2017 |
High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis. |
DAPT, IS, TIA |
| 64 |
2017 |
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack. |
TEG-ADPMA, TIA |
| 65 |
2017 |
On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel. |
--- |
| 66 |
2017 |
Optimal Same-Day Platelet Inhibition in Patients Receiving Drug-Eluting Stents With or Without Previous Maintenance Thienopyridine Therapy: from the Evaluation of Platelet Inhibition in Patients Having A VerifyNow Assay (EPIPHANY) Trial. |
EPIPHANY, PCI |
| 67 |
2017 |
Proteinuria Predicts Resistance to Antiplatelet Therapy in Ischemic Stroke. |
--- |
| 68 |
2017 |
Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese. |
--- |
| 69 |
2017 |
Thromboxane Formation Assay to Identify High On-Treatment Platelet Reactivity to Aspirin. |
AA, LTA, TX |
| 70 |
2017 |
Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. |
LTPR, PCI |
| 71 |
2017 |
[Predictive value of serial platelet function testing on outcome in patients undergoing complex percutaneous coronary intervention]. |
DAPT, MACCE, PCI, PFT |
| 72 |
2016 |
Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. |
ADP, GP, STEMI |
| 73 |
2016 |
Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. |
DES, MEA, PCI |
| 74 |
2016 |
Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients. |
COX, CVEs, TX |
| 75 |
2016 |
Clinical significance of platelet reactivity during prasugrel therapy in patients with acute myocardial infarction. |
AMI, CI, OR, PCI, PR |
| 76 |
2016 |
Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study. |
CEA, MEA |
| 77 |
2016 |
Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. |
--- |
| 78 |
2016 |
Does Pantoprazole Affect the On-Treatment Platelet Reactivity in Patients With Acute STEMI Treated With ADP Receptor Blockers?-A Pilot Prospective Study. |
ADP, PPI, STEMI |
| 79 |
2016 |
Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy. |
ACS, TPR, VASP |
| 80 |
2016 |
Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS). |
PCI |
| 81 |
2016 |
Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction. |
MCP, PCI, PRI, STEMI |
| 82 |
2016 |
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. |
CAD, LTPR |
| 83 |
2016 |
Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. |
MACEs |
| 84 |
2016 |
High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction. |
DPR, HR, MI, PRA, PRC |
| 85 |
2016 |
Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. |
ACS, LD, MD, PCI, VASP |
| 86 |
2016 |
Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients. |
ACS, LTPR, TEG, TIMI |
| 87 |
2016 |
The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions. |
PCI |
| 88 |
2016 |
Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. |
AU, CI, LD, MD, PCI |
| 89 |
2016 |
Type 2 Diabetes and ADP Receptor Blocker Therapy. |
T2D |
| 90 |
2015 |
Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. |
--- |
| 91 |
2015 |
Antiplatelet effects of aspirin in chronic kidney disease patients. |
CI, CKD, IQR |
| 92 |
2015 |
Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure. |
ASD, LTA, PFO, VASP |
| 93 |
2015 |
Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients. |
ACS, AU, MEA, PCI |
| 94 |
2015 |
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. |
CI, IM, LOF, PG-PRT, QALYs |
| 95 |
2015 |
CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome. |
ACS, ADP, EMs, GOF, IMs, LOF, PIR, PMs, TEG |
| 96 |
2015 |
High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis. |
CI, CV, MD, RR |
| 97 |
2015 |
High On-Treatment Platelet Reactivity Associated With Prasugrel. |
MI |
| 98 |
2015 |
High on-treatment platelet reactivity in transcatheter aortic valve implantation patients. |
DAPT, LTPR, TAVI |
| 99 |
2015 |
High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. |
--- |
| 100 |
2015 |
Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. |
ADP, LTPR |
|
A Search Service for Abbreviation / Long Form
